Optipharm KRX:153710KOSDAQ
옵티팜 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Optipharm reported revenue of ₩6.6bn, up 13.8% year on year, and an operating loss of ₩206m. Optipharm (옵티팜) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Insider buying 4 quarters of losses Screener
Optipharm quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩6.6bn | +13.8% | −₩206m margin −3.1% | −₩217m |
| Q1 2026 | ₩5.4bn | +9.0% | −₩723m margin −13.5% | −₩754m |
| Q4 2025 derived | ₩6.0bn | +6.5% | −₩321m margin −5.4% | −₩343m |
| Q3 2025 | ₩5.7bn | +18.6% | −₩525m margin −9.2% | −₩547m |
| Q2 2025 | ₩5.8bn | +16.9% | −₩434m margin −7.5% | −₩470m |
| Q1 2025 | ₩4.9bn | +14.4% | −₩1.1bn margin −23.1% | −₩1.1bn |
| Q4 2024 derived | ₩5.6bn | +10.9% | −₩251m margin −4.5% | −₩229m |
| Q3 2024 | ₩4.8bn | +12.3% | −₩546m margin −11.4% | −₩526m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Optipharm top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Optipharm news Korean headlines
No articles yet.